Shattuck Labs (NASDAQ:STTK) Stock Rating Upgraded by Leerink Partnrs

Leerink Partnrs upgraded shares of Shattuck Labs (NASDAQ:STTK) to a strong-buy rating in a research note published on Monday morning,Zacks.com reports.

Separately, Leerink Partners began coverage on Shattuck Labs in a report on Monday. They issued an “outperform” rating and a $4.00 price target for the company. Four investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Shattuck Labs Stock Up 2.6 %

Shattuck Labs stock opened at $1.19 on Monday. The stock has a 50-day simple moving average of $1.24 and a 200 day simple moving average of $1.59. Shattuck Labs has a 12-month low of $0.94 and a 12-month high of $11.76. The stock has a market capitalization of $56.81 million, a price-to-earnings ratio of -0.78 and a beta of 1.66.

Institutional Trading of Shattuck Labs

A number of hedge funds have recently modified their holdings of STTK. Adage Capital Partners GP L.L.C. raised its position in shares of Shattuck Labs by 61.2% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 4,675,000 shares of the company’s stock valued at $5,657,000 after acquiring an additional 1,775,000 shares during the period. 683 Capital Management LLC bought a new stake in Shattuck Labs during the 4th quarter worth approximately $1,270,000. Prosight Management LP increased its stake in Shattuck Labs by 15.1% during the 4th quarter. Prosight Management LP now owns 6,638,935 shares of the company’s stock worth $8,033,000 after purchasing an additional 873,409 shares in the last quarter. Takeda Pharmaceutical Co. Ltd. bought a new stake in Shattuck Labs during the 4th quarter worth approximately $624,000. Finally, Bank of America Corp DE increased its stake in Shattuck Labs by 135.0% during the 4th quarter. Bank of America Corp DE now owns 187,089 shares of the company’s stock worth $226,000 after purchasing an additional 107,491 shares in the last quarter. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.